Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5180458
Max Phase: Preclinical
Molecular Formula: C16H19N3O5
Molecular Weight: 333.34
Associated Items:
ID: ALA5180458
Max Phase: Preclinical
Molecular Formula: C16H19N3O5
Molecular Weight: 333.34
Associated Items:
Canonical SMILES: Cc1oc(CN(C)C(=O)CCc2nc(C3CC3)no2)cc1C(=O)O
Standard InChI: InChI=1S/C16H19N3O5/c1-9-12(16(21)22)7-11(23-9)8-19(2)14(20)6-5-13-17-15(18-24-13)10-3-4-10/h7,10H,3-6,8H2,1-2H3,(H,21,22)
Standard InChI Key: QFOSACYCLBYVKP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 333.34 | Molecular Weight (Monoisotopic): 333.1325 | AlogP: 2.14 | #Rotatable Bonds: 7 |
Polar Surface Area: 109.67 | Molecular Species: ACID | HBA: 6 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.13 | CX Basic pKa: | CX LogP: 1.21 | CX LogD: -1.89 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.83 | Np Likeness Score: -1.94 |
1. He S, Liu Y, Chu X, Li Q, Lyu W, Liu Y, Xing S, Feng F, Liu W, Guo Q, Zhao L, Sun H.. (2022) Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance., 13 (8.0): [PMID:35978698] [10.1021/acsmedchemlett.2c00175] |
Source(1):